RxDoctor Payments DataLook up a doctor →

Richard Teh, MD

Internal Medicine · Las Vegas, NVNPI 1538169008

Payments from drug & device makers

$13,780in general payments, 2019–2025

Across 505 payments — averaging $27.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Johnson & Johnson$1K
  • Amgen$993
  • Novo Nordisk$880
  • Lilly USA, LLC$596
  • plus $7K from 45 others

What the payments were for

  • Food & beverage$13,65499%
  • Education$1261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,780 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$232,038
Medicare patients
523
Services billed
2,961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$39,655
CreonLipase/Protease/Amylase13$36,645
MounjaroTirzepatide30$32,804
FarxigaDapagliflozin Propanediol36$30,013
EliquisApixaban39$29,466
JardianceEmpagliflozin36$29,208
ZenpepLipase/Protease/Amylase12$25,218
XareltoRivaroxaban18$15,168
JanuviaSitagliptin Phosphate14$14,823
InvokanaCanagliflozin12$6,746
Testosterone17$3,588
Advair DiskusFluticasone Propion/Salmeterol13$2,624
Omega-3 Acid Ethyl Esters33$1,898
SynthroidLevothyroxine Sodium24$1,664
Telmisartan56$1,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$880$39,65528 claims
AbbVieCreon, Synthroid$1,361$38,30937 claims
Lilly USA, LLCMounjaro$596$32,80430 claims
AstraZenecaFarxiga$1,805$30,01336 claims
PfizerEliquis$392$29,46639 claims
Boehringer IngelheimJardiance$566$29,20836 claims
Aimmune Therapeutics, Inc.Zenpep$441$25,21812 claims
Johnson & JohnsonXarelto, Invokana$1,248$21,91430 claims
MerckJanuvia$230$14,82314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →